MedPath

A Phase III Study of IPD-1151T in Patients With Interstitial Cystitis

Phase 3
Conditions
Interstitial cystitis
Registration Number
JPRN-jRCT2080220253
Lead Sponsor
Taiho Pharmaceutical Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1)20 years and older
2)Interstitial cystitis-characteristic findings observed by cystoscope under
hydrodistension
3)Stable for 12 weeks and more following hydrodistension of the bladder
4)IC symptom score of 7 and higher at the end of 2-week observation period
5)Pain score including bladder pain of 4 and higher

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement of IC symptom score and incidence of adverse drug reactions
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath